Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RecQ-mediated genome instability protein 2 (RMI2) is a small, evolutionarily conserved accessory protein within the BLM complex (consisting of BLM helicase, Topoisomerase IIIα, RMI1, and RMI2). RMI2 contains a single OB-fold, enabling protein-protein interactions rather than direct nucleic acid binding. Its critical function is to stabilize the BLM complex by interacting with RMI1 via hydrophobic and electrostatic contacts, enabling the dissolution of double Holliday junction intermediates—key DNA repair events that suppress crossovers and maintain chromosomal stability. It is required for proper mitotic and meiotic recombination, suppresses inappropriate sister chromatid exchange, and is essential for preventing genome instability. Loss or mutation of RMI2 (or BLM complex disruption) is linked to increased genome instability and the cancer-prone disorder Bloom syndrome[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RecQ-mediated genome instability protein 2 (RMI2).